Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 3,088,368 shares, a drop of 53.7% from the November 30th total of 6,675,820 shares. Based on an average daily volume of 737,184 shares, the days-to-cover ratio is currently 4.2 days. Approximately 6.4% of the shares of the stock are sold short. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily volume of 737,184 shares, the days-to-cover ratio is currently 4.2 days.

Xilio Therapeutics Stock Performance

XLO stock opened at $0.66 on Friday. Xilio Therapeutics has a one year low of $0.62 and a one year high of $1.70. The firm has a market cap of $34.75 million, a PE ratio of -1.02 and a beta of -0.07. The firm’s 50 day moving average price is $0.74 and its 200-day moving average price is $0.73.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%.The company had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.64 million. Equities research analysts predict that Xilio Therapeutics will post -1.14 EPS for the current fiscal year.

Institutional Trading of Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. ADAR1 Capital Management LLC bought a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 40,000 shares of the company’s stock, valued at approximately $29,000. ADAR1 Capital Management LLC owned about 0.08% of Xilio Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 54.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Xilio Therapeutics in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $2.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.